RPN2-mediated glycosylation of tetraspanin CD63 regulates breast cancer cell malignancy

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Tominaga, Naoomi ^a,b   Hagiwara, Keitaro ^a,c   Kosaka, Nobuyoshi ^a   Honma, Kimi ^a   Nakagama, Hitoshi ^a,b   Ochiya, Takahiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD63 ANTIGEN; GLYCOPEPTIDASE; GLYCOPROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; RIBOPHORIN 2; UNCLASSIFIED DRUG; CD63 PROTEIN, HUMAN; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; PROTEASOME; RIBOPHORIN; RPN2 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER PATIENT; CELL INVASION; CELL MEMBRANE; CELL SURFACE; CONTROLLED STUDY; DRUG RESISTANCE; GENE SILENCING; GLYCOSYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPH NODE METASTASIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TISSUE MICROARRAY; ADULT; AGED; BREAST TUMOR; CANCER STAGING; FEMALE; GENETICS; MCF 7 CELL LINE; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTIGENS, CD63; BREAST NEOPLASMS; FEMALE; GLYCOSYLATION; HUMANS; LYMPHATIC METASTASIS; MCF-7 CELLS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; P-GLYCOPROTEIN; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 84903272721     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-134     Document Type: Article

References (21)

1. Tarrant JM, Robb L, van Spriel AB, Wright MD. Tetraspanins: molecular organisers of the leukocyte surface. Trends Immunol 2003, 24:610-617. 10.1016/j.it.2003.09.011, 14596886.
2. Hemler ME. Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu Rev Cell Dev Biol 2003, 19:397-422. 10.1146/annurev.cellbio.19.111301.153609, 14570575.
3. Hotta H, Ross AH, Huebner K, Isobe M, Wendeborn S, Chao MV, Ricciardi RP, Tsujimoto Y, Croce CM, Koprowski H. Molecular cloning and characterization of an antigen associated with early stages of melanoma tumor progression. Cancer Res 1988, 48:2955-2962.
4. Duffield A, Kamsteeg EJ, Brown AN, Pagel P, Caplan MJ. The tetraspanin CD63 enhances the internalization of the H, K-ATPase beta-subunit. Proc Natl Acad Sci U S A 2003, 100:15560-15565. 10.1073/pnas.2536699100, 307607, 14660791.
5. Pols MS, Klumperman J. Trafficking and function of the tetraspanin CD63. Exp Cell Res 2009, 315:1584-1592. 10.1016/j.yexcr.2008.09.020, 18930046.
6. Latysheva N, Muratov G, Rajesh S, Padgett M, Hotchin NA, Overduin M, Berditchevski F. Syntenin-1 is a new component of tetraspanin-enriched microdomains: mechanisms and consequences of the interaction of syntenin-1 with CD63. Mol Cell Biol 2006, 26:7707-7718. 10.1128/MCB.00849-06, 1636879, 16908530.
7. Ageberg M, Lindmark A. Characterisation of the biosynthesis and processing of the neutrophil granule membrane protein CD63 in myeloid cells. Clin Lab Haematol 2003, 25:297-306. 10.1046/j.1365-2257.2003.00541.x, 12974720.
8. Radford KJ, Mallesch J, Hersey P. Suppression of human melanoma cell growth and metastasis by the melanoma-associated antigen CD63 (ME491). Int J Cancer 1995, 62:631-635. 10.1002/ijc.2910620523, 7665237.
9. Honma K, Iwao-Koizumi K, Takeshita F, Yamamoto Y, Yoshida T, Nishio K, Nagahara S, Kato K, Ochiya T. RPN2 gene confers docetaxel resistance in breast cancer. Nat Med 2008, 14:939-948. 10.1038/nm.1858, 18724378.
10. Hakomori S. Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res 1985, 45:2405-2414.
11. Takahashi RU, Takeshita F, Honma K, Ono M, Kato K, Ochiya T. Ribophorin II regulates breast tumor initiation and metastasis through the functional suppression of GSK3β. Sci Rep 2013, 3:2474. 3747512, 23959174.
12. Callen DF, Baker E, Simmers RN, Seshadri R, Roninson IB. Localization of the human multiple drug resistance gene, MDR1, to 7q21.1. Hum Genet 1987, 77:142-144. 10.1007/BF00272381, 3477522.
13. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002, 53:615-627. 10.1146/annurev.med.53.082901.103929, 11818492.
14. Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H, Haga N. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 2003, 94:15-21. 10.1111/j.1349-7006.2003.tb01345.x, 12708468.
15. Yoshida T, Ebina H, Koyanagi Y. N-linked glycan-dependent interaction of CD63 with CXCR4 at the Golgi apparatus induces downregulation of CXCR4. Microbiol Immunol 2009, 53:629-635. 10.1111/j.1348-0421.2009.00167.x, 19903263.
16. Berditchevski F, Tolias KF, Wong K, Carpenter CL, Hemler ME. A novel link between integrins, transmembrane-4 superfamily proteins (CD63 and CD81), and phosphatidylinositol 4-kinase. J Biol Chem 1997, 272:2595-2598. 10.1074/jbc.272.5.2595, 9006891.
17. Jung KK, Liu XW, Chirco R, Fridman R, Kim HR. Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J 2006, 25:3934-3942. 10.1038/sj.emboj.7601281, 1560352, 16917503.
18. Skubitz KM, Campbell KD, Skubitz AP. CD63 associates with CD11/CD18 in large detergent-resistant complexes after translocation to the cell surface in human neutrophils. FEBS Lett 2000, 469:52-56. 10.1016/S0014-5793(00)01240-0, 10708755.
19. Li L, Jiang AC, Dong P, Wang H, Xu W, Xu C. MDR1/P-gp and VEGF synergistically enhance the invasion of Hep-2 cells with multidrug resistance induced by taxol. Ann Surg Oncol 2009, 16:1421-1428. 10.1245/s10434-009-0395-7, 19247716.
20. Huang CI, Kohno N, Ogawa E, Adachi M, Taki T, Miyake M. Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients. Am J Pathol 1998, 153:973-983. 10.1016/S0002-9440(10)65639-8, 1853017, 9736046.
21. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105:10513-10518. 10.1073/pnas.0804549105, 2492472, 18663219.